ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2450

Examination of the Clinical Significance of 14-3-3 Eta in Juvenile Idiopathic Arthritis

Lance Feller1, Austin M. Dalrymple2, Paul Tuttle IV3, Reema H. Syed3, Peri Pepmueller1 and Terry Moore4, 1Rheumatology, Saint Louis University, St. Louis, MO, 2Pediatric Rheumatology, St. Louis University, St. Louis, MO, 3IM-Rheumatology, Saint Louis University, St. Louis, MO, 4Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, citrullination and juvenile arthritis, Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription regulation. Recent work has implicated the η (eta) isoform as having diagnostic potential in inflammatory arthritis. Its utility and significance in juvenile idiopathic arthritis (JIA) has not been established, but our prior investigation revealed 14-3-3η positivity in some JIA patients. In this study we investigated the utility of measuring 14-3-3η in children with juvenile idiopathic arthritis.

Methods:

Measurements of 14-3-3η were obtained during evaluations of new patients with joint pain and in routine follow-up of JIA patients presenting between July 2013 and April of 2015. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP Ab) were measured. A chart review was later conducted to evaluate the clinical significance 14-3-3η. Joint imaging was evaluated for erosive changes.

Results:

23 JIA patients were evaluated. 10 had polyarticular disease, 3 had oligoarticular extended, 3 had seronegative spondyloarthritis (SNSA), 2 had oligoarticular, 2 were undifferentiated, 2 had enthesitis-related arthritis (ERA), and 1 had systemic-onset.

7 of 23 were 14-3-3η positive (5 had polyarticular disease, 1 with ERA, & 1 with oligoarticular). All 5 patients with polyarticular disease also were RF positive and 3 were both RF & anti-CCP Ab positive. The ERA patient was seronegative, and the oligoarticular patient was positive only for RF.

9 of the 23 had erosive disease, 4 of which were polyarticular with a positive 14-3-3η. Of those 1 was RF positive, and the remaining 3 patients were positive for RF and anti-CCP Ab.  Neither the 14-3-3η positive patient with ERA nor the one with oligoarticular disease had erosions.

Conclusion:

14-3-3η can be found in polyarticular JIA and correlates with a positive RF and to a lesser extent a positive anti-CCP Ab.  The majority of polyarticular JIA patients with erosions were 14-3-3η positive.  We hope to expand this small study to include a larger sample and evaluate for any further relationships.


Disclosure: L. Feller, None; A. M. Dalrymple, None; P. Tuttle IV, None; R. H. Syed, None; P. Pepmueller, None; T. Moore, None.

To cite this abstract in AMA style:

Feller L, Dalrymple AM, Tuttle P IV, Syed RH, Pepmueller P, Moore T. Examination of the Clinical Significance of 14-3-3 Eta in Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/examination-of-the-clinical-significance-of-14-3-3-eta-in-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/examination-of-the-clinical-significance-of-14-3-3-eta-in-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology